Trial Endpoints in Prostate Cancer

April 4, 2014
Robert Dreicer, MD, MS

Robert Dreicer, MD, MS, Cleveland Clinic Lerner College of Medicine, Department of Solid Tumor Oncology, Taussig Cancer Institute, comments on current clinical trial endpoints in prostate cancer.

Clinical Pearls

Robert Dreicer, MD, MS, professor of medicine at the Cleveland Clinic Lerner College of Medicine, chairman, Department of Solid Tumor Oncology, Taussig Cancer Institute, comments on current clinical trial endpoints in prostate cancer.

  • Current trial endpoints needed for regulatory approval take longer to achieve in earlier disease states
  • Until intermediate endpoints are applied in this disease, survival endpoints will remain difficult to reach in some disease stages